Analyzing Bayer Aktiengesellschaft (OTCMKTS:BAYRY) & Genprex (NASDAQ:GNPX)

Genprex (NASDAQ:GNPX) and Bayer Aktiengesellschaft (OTCMKTS:BAYRY) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, earnings, risk and analyst recommendations.

Profitability

This table compares Genprex and Bayer Aktiengesellschaft’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Genprex	N/A	-318.57%	-224.95%
Bayer Aktiengesellschaft	-2.74%	16.96%	4.95%

Risk and Volatility

Genprex has a beta of -1.3, meaning that its share price is 230% less volatile than the S&P 500. Comparatively, Bayer Aktiengesellschaft has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500.

Institutional & Insider Ownership

14.1% of Genprex shares are owned by institutional investors. 8.5% of Genprex shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for Genprex and Bayer Aktiengesellschaft, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genprex	0	0	1	0	3.00
Bayer Aktiengesellschaft	1	8	0	0	1.89

Genprex currently has a consensus target price of $10.00, suggesting a potential upside of 452.49%. Given Genprex’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Genprex is more favorable than Bayer Aktiengesellschaft.

Valuation and Earnings

This table compares Genprex and Bayer Aktiengesellschaft”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genprex	N/A	N/A	-$30.86 million	N/A	N/A
Bayer Aktiengesellschaft	$51.55 billion	0.52	-$3.18 billion	($0.36)	-18.78

Genprex has higher earnings, but lower revenue than Bayer Aktiengesellschaft.

Summary

Genprex beats Bayer Aktiengesellschaft on 7 of the 11 factors compared between the two stocks.

About Genprex

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines for self-medication and self-care; and solutions for nutritional supplements, allergy, cough and cold, dermatology, pain and cardiovascular risk prevention, and digestive health. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration with Acuitas Therapeutics, Inc. to strengthen gene editing programs; Peking University in the area of basic pharmaceutical research; the Swiss Tropical and Public Health Institute in the development of the compound emodepside for the treatment of infection with soil-transmitted helminths; bit.bio Ltd. for the discovery and manufacture of regulatory T cells for use in creating therapeutics; Hologic, Inc. in the field of contrastenhanced-mammography solutions to improve diagnostic imaging for the detection of breast cancer; and Twist Bioscience Corporation centering around the research and development of antibody-based pharmaceuticals, as well as with CrossBay Medical Inc. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company has collaboration with Thermo Fisher Scientific. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.